Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.34 CAD | -5.56% | -19.05% | +41.67% |
04-12 | Sona Nanotech Provides Interim Results of Dalhousie Study | MT |
04-12 | Sona Nanotech Provides Interim Results of Dalhousie Efficacy Study | CI |
Valuation
Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Capitalization 1 | 12.53 | 10.97 | 216.3 | 21.18 | 10 | 16.64 |
Enterprise Value (EV) 1 | 11.81 | 11.55 | 217.6 | 21.32 | 10.45 | 17.05 |
P/E ratio | -1.27 x | -4.13 x | -33.9 x | -2.04 x | -4.2 x | -6 x |
Yield | - | - | - | - | - | - |
Capitalization / Revenue | - | - | - | - | - | - |
EV / Revenue | - | - | - | - | - | - |
EV / EBITDA | -10.7 x | -7.19 x | -37 x | -2.02 x | -3.53 x | -7.93 x |
EV / FCF | 2.87 x | -6.07 x | 793 x | 34.8 x | -7.02 x | -135 x |
FCF Yield | 34.8% | -16.5% | 0.13% | 2.88% | -14.2% | -0.74% |
Price to Book | 64.4 x | -10.7 x | -63 x | -17.6 x | -19.7 x | 14.3 x |
Nbr of stocks (in thousands) | 52,200 | 57,730 | 61,264 | 64,185 | 68,988 | 95,095 |
Reference price 2 | 0.2400 | 0.1900 | 3.530 | 0.3300 | 0.1450 | 0.1750 |
Announcement Date | 19-02-27 | 20-02-28 | 21-03-01 | 22-02-28 | 23-02-27 | 24-02-27 |
Income Statement Evolution (Annual data)
Fiscal Period: October | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net sales | - | - | - | - | - | - |
EBITDA 1 | -1.108 | -1.605 | -5.888 | -10.56 | -2.956 | -2.15 |
EBIT 1 | -1.136 | -1.656 | -5.954 | -10.63 | -3.017 | -2.607 |
Operating Margin | - | - | - | - | - | - |
Earnings before Tax (EBT) 1 | -5.196 | -2.521 | -6.272 | -10.37 | -2.361 | -2.5 |
Net income 1 | -5.196 | -2.521 | -6.272 | -10.37 | -2.361 | -2.5 |
Net margin | - | - | - | - | - | - |
EPS 2 | -0.1890 | -0.0460 | -0.1042 | -0.1619 | -0.0345 | -0.0291 |
Free Cash Flow 1 | 4.109 | -1.902 | 0.2744 | 0.6134 | -1.489 | -0.126 |
FCF margin | - | - | - | - | - | - |
FCF Conversion (EBITDA) | - | - | - | - | - | - |
FCF Conversion (Net income) | - | - | - | - | - | - |
Dividend per Share | - | - | - | - | - | - |
Announcement Date | 19-02-27 | 20-02-28 | 21-03-01 | 22-02-28 | 23-02-27 | 24-02-27 |
Balance Sheet Analysis
Fiscal Period: oktober | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 |
---|---|---|---|---|---|---|
Net Debt 1 | - | 0.58 | 1.38 | 0.14 | 0.44 | 0.41 |
Net Cash position 1 | 0.72 | - | - | - | - | - |
Leverage (Debt/EBITDA) | - | -0.3603 x | -0.2344 x | -0.0132 x | -0.1502 x | -0.1917 x |
Free Cash Flow 1 | 4.11 | -1.9 | 0.27 | 0.61 | -1.49 | -0.13 |
ROE (net income / shareholders' equity) | 1,735% | 612% | 281% | 445% | 273% | -764% |
ROA (Net income/ Total Assets) | -40.4% | -51.3% | -470% | -591% | -184% | -99.7% |
Assets 1 | 12.86 | 4.916 | 1.335 | 1.754 | 1.28 | 2.508 |
Book Value Per Share 2 | 0 | -0.0200 | -0.0600 | -0.0200 | -0.0100 | 0.0100 |
Cash Flow per Share 2 | 0.0300 | 0.0100 | 0 | 0.0200 | 0 | 0 |
Capex 1 | 0.15 | 0.16 | 0.38 | - | - | - |
Capex / Sales | - | - | - | - | - | - |
Announcement Date | 19-02-27 | 20-02-28 | 21-03-01 | 22-02-28 | 23-02-27 | 24-02-27 |
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
1st Jan change | Capi. | |
---|---|---|
+41.67% | 25.97M | |
-3.15% | 184B | |
-1.34% | 107B | |
-4.01% | 67.78B | |
+2.41% | 50.66B | |
+11.71% | 47.64B | |
+4.60% | 41.12B | |
+1.92% | 26.3B | |
+1.90% | 26.04B | |
+15.06% | 25.4B |
- Stock Market
- Equities
- SONA Stock
- Financials Sona Nanotech Inc.